Table 7.
Intervened Participants with Adverse Events by System Organ Class
| System Organ Class | MKP | Placebo | P value |
|---|---|---|---|
| (n = 134) | (n = 131) | ||
| n (%) | n (%) | ||
| Infections and infestations | 52 (38.8) | 54 (41.2) | 0.708 |
| Nervous system disorders | 16 (11.9) | 14 (10.7) | 0.847 |
| Gastrointestinal disorders | 13 (9.7) | 15 (11.5) | 0.693 |
| Musculoskeletal and connective tissue disorders | 7 (5.2) | 9 (6.9) | 0.615 |
| Respiratory, thoracic and mediastinal disorders | 5 (3.7) | 8 (6.1) | 0.408 |
| General disorders and administration site conditions | 2 (1.5) | 1 (0.8) | 1.000 |
| Injury, poisoning and procedural complications | 2 (1.5) | 2 (1.5) | 1.000 |
| Cardiac disorders | 1 (0.7) | 1 (0.8) | 1.000 |
| Immune system disorders | 1 (0.7) | 2 (1.5) | 0.619 |
| Neoplasms benign, malignant and unspecified | 1 (0.7) | 2 (1.5) | 0.619 |
| Renal and urinary disorders | 1 (0.7) | 0 (0.0) | 1.000 |
| Reproductive system and breast disorders | 1 (0.7) | 0 (0.0) | 1.000 |
| Skin and subcutaneous tissue disorders | 1 (0.7) | 5 (3.8) | 0.117 |
| Ear and labyrinth disorders | 0 (0.0) | 1 (0.8) | 0.494 |
Note: P values were derived by the Fisher’s exact test.
Abbreviation: MKP, Met-Lys-Pro.